Navigation Links
Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
Date:12/15/2007

udy found that the Recurrence Score result was a highly significant predictor of recurrence in both node-negative disease (p=0.0007) and node-positive disease (p=0.0004). In addition, a low Recurrence Score result predicted a low likelihood of recurrence regardless of nodal status.

"In examining the relationship between the Oncotype DX Recurrence Score and Adjuvant Online, we found that both tools have value in providing crucial information on the likelihood of breast cancer recurrence," said Peter Ravdin, M.D., Ph.D., the M.D. Anderson Cancer Center physician who developed the Adjuvant Online tool and a co-author of the study. "Specifically, the addition of Oncotype DX Recurrence Score results yielded supplementary insight on outcomes for breast cancer patients. Used together, we have the opportunity to more effectively guide personal treatment decisions based on a woman's individual breast cancer."

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please vi
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive ... a platform to think outside the bra. She doesn’t try ... to raise awareness about women’s other lady parts. , "We ... say the color pink and everybody knows what you’re talking ... that it has not been won when it comes to ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... Akron, OH (PRWEB) October 20, 2014 ... new Assisted Living Center on Oct. 14. The $11 ... amenities and services, and a cooked-to-order kitchen with full-service ... forward Akron’s premier choice for first class Assisted Living ... groundbreaking. “Our residents deserve the highest quality of care ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... day in health-related lost productivity equals 56 cents per share ... 8 /PRNewswire/ -- In today,s challenging economy every ... for business success. To help companies make the business case ... a DVD about the experience of a Fortune 500 company ...
... Blue Cross and Blue Shield of Georgia,(BCBSGa) today announced ... more than 996 not-for-profit organizations in 2009 as part,of the ... of Georgia Foundation will match 50 percent of associate pledges,increasing ... "Every day our associates work to ...
... The end of fall marks an exciting time,for ... their,professional careers. Fellows from around the world will gather ... Interventions (SCAI),Third Annual Interventional Cardiology Fall Fellows Course in ... Given the aging population and the increasing number ...
... low risk of developing intractable disease , , MONDAY, Dec. ... giving anti-seizure medication to children with epilepsy who,ve achieved ... at high risk of later developing intractable epilepsy, a ... affects about 10 percent of children with epilepsy, is ...
... drug treatment, researchers note , , MONDAY, Dec. 8 (HealthDay ... genes of more than 40,000 people has identified 11 ... as LDL cholesterol and triglycerides. , "These locations point ... cholesterol in humans," said Dr. Sekar Kathiresan, director of ...
... Inc.,(Nasdaq: ARNA ) announced today that ... Monday, December 15, 2008, beginning at approximately 12:00 ... Jack Lief,President and Chief Executive Officer, Dominic P. ... and William R. Shanahan, M.D., Vice,President and Chief ...
Cached Medicine News:Health News:Integrated Benefits Institute Helps Employers Make the Business Case for Health and Productivity Improvement 2Health News:Blue Cross and Blue Shield of Georgia Associates Pledge More Than $1.3 Million to Community Organizations 2Health News:Blue Cross and Blue Shield of Georgia Associates Pledge More Than $1.3 Million to Community Organizations 3Health News:SCAI's Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field 2Health News:SCAI's Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field 3Health News:Seizure Meds Can Be Safely Withdrawn From Kids With Epilepsy 2Health News:11 New Cholesterol Genes Identified 2Health News:11 New Cholesterol Genes Identified 3Health News:Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008 2Health News:Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008 3
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... its Medical Software Advice website ( www.softwareadvice.com/medical ), a ... the right technology for their practices. , , ,"The ... vendor landscape is more fragmented than ever," said Don ... "We aim to bring clarity to the market ...
... 17 Scimitar Equity Research, Inc. issues a,review ... Promising Therapeutic and Vaccine Candidate for the Treatment ... analyst research is,available on Scimitar,s website: http://www.scimitarequity.com ... developing innovative therapeutics for the treatment of viral,infections ...
Cached Medicine Technology:Physicians Will Benefit from Medical Software Advice Website 2Initiation of Coverage Informational Review Issued by Scimitar Equity Research 2
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... Radiolucent Retractors for ... Excellent spinal exposure on ... for outstanding exposure during ... instrumentation. May be accessorized ...
... generation interbody fusion device. Rhakoss implants ... alternative to titanium/carbon fiber cages and ... the best features of first generation ... disadvantages of current available materials, such ...
As a unique complement to the spinal concepts family of products....
Medicine Products: